Please Wait
Applying Filters...
menu
    • menu
    Top news of 2025: Drugmakers invest in US capacities, agree to lower Medicaid prices; Pfizer buys obesity-focused biotech Metsera

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    Inebilizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    30/12/2025 AstraZeneca
    United Kingdom
    		 AstraZeneca Pharmaceuticals LP 303MF40004 Culture medium/culture medium additives・Inebelizumab ... 2021-01-26 2021-01-26 One MedImmune Way, Gaithersburg, MD 20878, USA
    30/12/2025 AstraZeneca
    United Kingdom
    		 AstraZeneca Pharmaceuticals LP 303MF40003 Culture medium/culture medium additives - Inebilizumab ... 2021-01-26 2021-01-26 One MedImmune Way, Gaithersburg, MD 20878, USA
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.